ArticleFrontiers in pharmacology2021

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).

Daniel Heudobler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.